Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (RPCEC00000461) titled 'Efficacy and safety of the monoclonal antibody nimotuzumab plus FOLFOX vs. FOLFOX as first-line treatment of patients with unresectable, left-sided, metastatic colorectal cancer. Phase I/II' on Aug. 12.
Study Type: Interventional
Study Design:
Allocation: Randomized controlled trial. Masking: Open. Control group: Active. Assignment: Parallel. Purpose: Treatment
Primary Sponsor: Center of Molecular Immunology (CIM)
Condition:
Metastatic colorectal cancer, left-sided, unresectable
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Rectal Diseases
Colonic Diseases
Intes...